Correction to: Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program

Eric L Simpson; Jonathan I Silverberg; Audrey Nosbaum; Kevin L Winthrop; Emma Guttman-Yassky; Karin M Hoffmeister; Alexander Egeberg; Hernan Valdez; Min Zhang; Saleem A Farooqui; William Romero; Andrew J Thorpe; Ricardo Rojo; Susan Johnson

doi:10.1007/s40257-021-00638-z

Correction to: Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program

Eric L Simpson, Jonathan I Silverberg, Audrey Nosbaum, Kevin L Winthrop, Emma Guttman-Yassky, Karin M Hoffmeister, Alexander Egeberg, Hernan Valdez, Min Zhang, Saleem A Farooqui, William Romero, Andrew J Thorpe, Ricardo Rojo, Susan Johnson

Dermatology, Department of

3 Citations (Scopus)

Abstract

SpringerLink on 18 August 2021. After publication in volume 22, issue 5, pages 693–707, the authors highlighted that, in Supplemental Table 1, the overall patient numbers for the JADE MONO-2 and JADE COMPARE studies were incorrect. These errors have been rectified and a new corrected version of Supplementary file 1 has been uploaded with the manuscript on SpringerLink. The original article has been corrected.

Original language	English
Publication date	Nov 2021
Edition	6
Volume	22
Number of pages	1
DOIs	https://doi.org/10.1007/s40257-021-00638-z
Publication status	Published - Nov 2021

Series	American Journal of Clinical Dermatology
ISSN	1175-0561

Access to Document

10.1007/s40257-021-00638-z

Cite this

Simpson, E. L., Silverberg, J. I., Nosbaum, A., Winthrop, K. L., Guttman-Yassky, E., Hoffmeister, K. M., Egeberg, A., Valdez, H., Zhang, M., Farooqui, S. A., Romero, W., Thorpe, A. J., Rojo, R., & Johnson, S. (2021, Nov). Correction to: Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program. (6 ed.) American Journal of Clinical Dermatology https://doi.org/10.1007/s40257-021-00638-z

Simpson, EL, Silverberg, JI, Nosbaum, A, Winthrop, KL, Guttman-Yassky, E, Hoffmeister, KM, Egeberg, A, Valdez, H, Zhang, M, Farooqui, SA, Romero, W, Thorpe, AJ, Rojo, R & Johnson, S 2021, Correction to: Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program.. https://doi.org/10.1007/s40257-021-00638-z

@misc{a1a7e7c8177a420ab9ed479f85210d4d,

title = "Correction to: Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program",

abstract = "SpringerLink on 18 August 2021. After publication in volume 22, issue 5, pages 693–707, the authors highlighted that, in Supplemental Table 1, the overall patient numbers for the JADE MONO-2 and JADE COMPARE studies were incorrect. These errors have been rectified and a new corrected version of Supplementary file 1 has been uploaded with the manuscript on SpringerLink. The original article has been corrected.",

author = "Simpson, {Eric L} and Silverberg, {Jonathan I} and Audrey Nosbaum and Winthrop, {Kevin L} and Emma Guttman-Yassky and Hoffmeister, {Karin M} and Alexander Egeberg and Hernan Valdez and Min Zhang and Farooqui, {Saleem A} and William Romero and Thorpe, {Andrew J} and Ricardo Rojo and Susan Johnson",

year = "2021",

month = nov,

doi = "10.1007/s40257-021-00638-z",

language = "English",

volume = "22",

series = "American Journal of Clinical Dermatology",

publisher = "Adis International Ltd",

edition = "6",

type = "Other",

}

TY - GEN

T1 - Correction to

T2 - Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program

AU - Simpson, Eric L

AU - Silverberg, Jonathan I

AU - Nosbaum, Audrey

AU - Winthrop, Kevin L

AU - Guttman-Yassky, Emma

AU - Hoffmeister, Karin M

AU - Egeberg, Alexander

AU - Valdez, Hernan

AU - Zhang, Min

AU - Farooqui, Saleem A

AU - Romero, William

AU - Thorpe, Andrew J

AU - Rojo, Ricardo

AU - Johnson, Susan

PY - 2021/11

Y1 - 2021/11

N2 - SpringerLink on 18 August 2021. After publication in volume 22, issue 5, pages 693–707, the authors highlighted that, in Supplemental Table 1, the overall patient numbers for the JADE MONO-2 and JADE COMPARE studies were incorrect. These errors have been rectified and a new corrected version of Supplementary file 1 has been uploaded with the manuscript on SpringerLink. The original article has been corrected.

AB - SpringerLink on 18 August 2021. After publication in volume 22, issue 5, pages 693–707, the authors highlighted that, in Supplemental Table 1, the overall patient numbers for the JADE MONO-2 and JADE COMPARE studies were incorrect. These errors have been rectified and a new corrected version of Supplementary file 1 has been uploaded with the manuscript on SpringerLink. The original article has been corrected.

U2 - 10.1007/s40257-021-00638-z

DO - 10.1007/s40257-021-00638-z

M3 - Other contribution

C2 - 34642878

VL - 22

T3 - American Journal of Clinical Dermatology

ER -

Correction to: Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program

Abstract

Access to Document

Fingerprint

Cite this